Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association